Trimeris names new CEO
Former GlaxoSmithKline Senior VP-Global Commercial Strategy Steven Skolsky takes top leadership slot at Trimeris effective Sept. 9. Skolsky succeeds company founder Dani Bolognesi, PhD, who is staying on as chief scientific officer. Skolsky's appointment fills a need for senior leadership following the departure of Trimeris' President Nixon Ellis, PhD, in June. At GSK, Skolsky's most recent post is being filled by Richard Wallace, who moved up from VP-global therapeutic area strategy for psychiatry...
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?